<DOC>
	<DOCNO>NCT02882425</DOCNO>
	<brief_summary>The primary purpose phase 1 study investigate absolute bio-availability single oral dose selexipag , i.e. , assess amount selexipag reach blood administered oral tablet ( ACT-293987 ) compare intravenous administration healthy subject .</brief_summary>
	<brief_title>Absolute Bioavailability Single Oral Dose Selexipag Healthy Subjects</brief_title>
	<detailed_description>A pilot phase conduct 3 male subject main phase assessment absolute bio-availability conduct 16 male subject . The pilot phase aim determine intravenous dose use main phase base safety data pharmacokinetics data .</detailed_description>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure Aged 18 45 ( inclusive ) screen Body mass index ( BMI ) 18.0 28.0 kg/m2 ( inclusive ) screen Healthy basis physical examination , cardiovascular assessment laboratory test Any contraindication study drug formulation History presence disease condition treatment , may put subject risk participation study may interfere absorption , distribution , metabolism excretion study drug Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>selexipag</keyword>
	<keyword>bioavailability</keyword>
</DOC>